GLOBAL-SAVINGS-GROUP
7.12.2022 16:40:39 CET | Business Wire | Press release
Global Savings Group (GSG) and Pepper.com (Pepper) have signed a deal to join forces, combining the world’s largest shopping community with Europe’s leading shopping recommendation and rewards company. The transaction marks the biggest deal in the industry in 2022 and creates a European Champion with a global footprint. Together, GSG and Pepper will form a multinational tech company empowering shoppers in more than 20 markets to make more confident shopping decisions. GSG and Pepper will jointly operate the world’s largest shopping community, recommendation and rewards platform connecting brands and retailers with consumers across more than 2bn purchase journeys annually.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130006042/en/
Fabian Spielberger (CEO and Founder Pepper.com) and Gerhard Trautmann (CEO and Co-founder Global Savings Group) are about to join forces. (Photo: Business Wire)
“We are incredibly excited about this industry-disrupting deal that reinforces our leading position in Europe. Together with Pepper, we will significantly enhance our ability to empower consumers and play an even more meaningful role in their daily lives which will open a wide field of development opportunities to shape the future of our industry together. Jointly, we will create a unique, impactful and even more comprehensive portfolio of shopping solutions with huge benefits for consumers, brands, retailers and publishers alike at a scale that's just not possible anywhere else. Together, we will increase our transformative impact and boost GSG’s growth”, states Dr. Gerhard Trautmann, CEO of GSG.
“Our primary focus has always been to offer the best and broadest of money saving solutions to our communities. Our collaboration with GSG will speed up this process significantly as it empowers us to branch out more. Combined, we have more than 20 years of experience in helping people to make smarter decisions and together we will provide even better and more rewarding shopping experiences. Our loyal customers and many more to come will benefit from our combined contents and technologies”, comments Fabian Spielberger, CEO of Pepper.
GSG and Pepper are both market leaders in their fields and have expanded their solutions and services through strategic acquisitions and organic growth. After the 2018 takeover of the UK loyalty specialist Pouch, GSG acquired iGraal and Shoop, the leading French and German cashback brands in 2020 and 2021 respectively, and just recently the US-based consumer brand and domain Coupons.com. Pepper has always shared GSG’s ambition to consolidate the fast-growing market in the sector and has expanded internationally since 2014. Today, Pepper operates market-leading social commerce platforms such as Dealabs, hotukdeals and mydealz. Together, GSG and Pepper will continue to develop and leverage technology to build the leading platform of shopping solutions and services to constantly drive future growth in current and new markets and verticals.
About GSG
GSG is Europe’s largest shopping rewards company with an international footprint across more than 20 markets. The company’s goal is to empower consumers to get more out of life by providing them access to best savings, cashback, deals, product inspiration, reviews and other digital shopping services. Founded in 2012 and headquartered in Munich, GSG employs more than 700 employees in 12 offices across the globe.
About Pepper
Pepper.com is the world's largest shopping community. From its headquarter in Berlin and offices in Guadalajara, London, Lyon and Winnipeg, the Pepper Media Holding operates market-leading social commerce platforms such as Dealabs, hotukdeals and mydealz.de which are used by 25 million consumers per month and influences 12,000 purchase decisions per minute. The company was founded in 2014 by Fabian Spielberger and Paul Nikkel.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221130006042/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 01:35:00 CEST | Press release
~ Creating Climate Solutions and New Market Opportunities through Source-Specific CO2 Emission and Uptake Monitoring via Satellite Constellation and Aircraft ~ Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Cap
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom